在刺激性肠综合征谱系障碍的个性化管理方法
Wolfgang J Schnedl1, Simon Michaelis2, Harald Mangge3
1Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, A-8036, Graz, Austria; General Internal Medicine Practice, Dr. Theodor Körnerstrasse 19b, A-8600, Bruck, Austria.
Clinical nutrition ESPEN
|September 22, 2023
概括
个性化的饮食干预和对H. pylori的测试对于管理刺激性肠综合征 (IBS) 谱系障碍至关重要,超越一种适合所有人的方法,以获得更好的患者结果.
科学领域:
- 胃肠病学 胃肠病学
- 临床营养学 临床营养学
- 微生物学 微生物学
背景情况:
- 刺激性肠综合征 (IBS) 频谱障碍,伴有各种食后腹部症状.
- 目前对IBS的饮食治疗方法在很大程度上是普遍的,缺乏个性化和强有力的科学证据.
- IBS的病理生理学仍然不清楚,尽管症状与食物不耐受性/吸收不良综合征重叠.
研究的目的:
- 批评IBS频谱障碍的一般饮食方法的有效性.
- 倡导针对食物不耐受/吸收不良和H. pylori的个性化诊断工作.
- 根据个体患者发现,推量身定制的饮食干预措施.
主要方法:
- 审查目前的"适合所有人"的IBS饮食策略,包括排除饮食和低FODMAP饮食.
- 讨论IBS症状与诸如乳病,果糖吸收不良,胰岛素不耐受,乳糖不耐受和H. pylori感染等疾病之间的联系.
- 关于一种非侵入性诊断方法的建议,以确定IBS患者的潜在病理生理因素.
主要成果:
- 对于IBS频谱障碍的复杂性质,通用饮食治疗是不够的.
- 食物不耐受/吸收不良和H. pylori感染是IBS类症状的重要因素.
- 个性化诊断对于有效管理至关重要.
结论:
- 适合所有人的饮食干预措施对于IBS谱系障碍是无效的,应该阻止它们.
- 建议进行全面的诊断工作,包括对食物不耐受性/吸收不良和H. pylori的测试.
- 由注册营养学家指导的个性化饮食计划,在必要时与H. pylori根除疗法一起,提供最有效的治疗策略.
相关概念视频
Irritable Bowel Syndrome III: Medical and Nursing Management
225
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
225
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
348
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
348
Inflammatory Bowel Disease IV: Pharmacological Management
145
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
145
Irritable Bowel Syndrome I: Introduction
304
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
304
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
181
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
181
Drugs for Treatment of Diarrhea-Predominant IBS
200
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
200


